Rhythm Biosciences Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RHY.AX research report →
Price Chart
About the company
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer.
- CEO
- David Atkins
- IPO
- 2017
- Employees
- 23
- HQ
- Parkville, VIC, AU
Get TickerSpark's AI analysis on RHY.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $31.14M
- P/E
- -3.88
- PEG
- 0.05
- P/S
- 436.30
- P/B
- 13.05
- EV/EBITDA
- -3.73
- Div Yield
- 0.00%
- Gross Margin
- -6405.08%
- Op Margin
- -11188.45%
- Net Margin
- -9353.35%
- ROE
- -476.27%
- ROIC
- -267.03%
Latest fiscal year · YoY change
- Revenue
- $3.19M+88.9%
- Gross Profit
- $2.97M+318.6%
- Op Income
- $-3,532,873
- Net Income
- $-3,829,371+44.2%
- EPS
- $-0.01+52.7%
- OCF Growth
- +52.4%
- FCF Growth
- +52.7%
- 52W High
- $0.28
- 52W Low
- $0.07
- 50D MA
- $0.09
- 200D MA
- $0.13
- Beta
- 0.41
- RSI (14)
- 50
- Avg Volume
- 274.16K
No earnings-call transcripts are available for RHY.AX yet.
- Free Float
- 92.6%
- Shares Outstanding
- 353.87M
- Float Shares
- 327.68M
Our RHY.AX coverage
Recent articles, reports, and earnings notes.
No research on RHY.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RHY.AX report →